APA (7th ed.) Citation

T, L., A, G., M, Y., EE, C., W, S., D, Y., . . . M, B. (2023). Cost-Effectiveness Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) Versus Standard of Care for the Prevention of Recurrent Clostridioides difficile Infection in the USA. Advances in therapy, 40(6), 2784. https://doi.org/10.1007/s12325-023-02505-1

Chicago Style (17th ed.) Citation

T, Lodise, Guo A, Yang M, Cook EE, Song W, Yang D, Wang Q, Zhao A, and Bochan M. "Cost-Effectiveness Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) Versus Standard of Care for the Prevention of Recurrent Clostridioides Difficile Infection in the USA." Advances in Therapy 40, no. 6 (2023): 2784. https://doi.org/10.1007/s12325-023-02505-1.

MLA (9th ed.) Citation

T, Lodise, et al. "Cost-Effectiveness Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) Versus Standard of Care for the Prevention of Recurrent Clostridioides Difficile Infection in the USA." Advances in Therapy, vol. 40, no. 6, 2023, p. 2784, https://doi.org/10.1007/s12325-023-02505-1.